No profile data available.
Tyra Biosciences, Inc. (TYRA) is a healthcare company in the additional cancer treatment drugs industry, based in Carlsbad, United States, with about 87 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$119.95 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $1.37 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States.
Tyra Biosciences reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$1.37 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Nuvation Bio Inc. (NUVB), Inhibrx Biosciences, Inc. (INBX), AnaptysBio, Inc. (ANAB), Replimune Group, Inc. (REPL).